Le Lézard
Classified in: Health
Subjects: CCA, PET, FVT

Heska Schedules Second Quarter 2018 Financial Results Conference Call for August 7, 2018


LOVELAND, Colo., July 18, 2018 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and specialty products, plans to announce its second quarter 2018 financial results in a press release to be issued on Tuesday, August 7, 2018 before the market opens. The Company plans to host a conference call to discuss the results at 9 a.m. MT / 11 a.m. ET on the same day, Tuesday, August 7, 2018.

To access the conference call:

    From within the United States, please dial 1-888-394-8218

    From outside of the United States, please dial 1-323-701-0225

    Reference Conference ID: 9053418

The conference call will be webcast live from the Company's website on www.heska.com.

A telephonic replay of the conference call will be available beginning at 2 p.m. ET and continue through 11:59 p.m. ET on Tuesday, August 14, 2018.

To access the replay:

    From within the United States, please dial 1-844-512-2921

    From outside the United States, please dial 1-412-317-6671

    Reference Replay Pin Number: 9053418

The webcast will also be archived on www.heska.com for 90 days.

About Heska

Heska Corporation (NASDAQ: HSKA - News) manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products. Heska's business is composed of Core Companion Animal Health ("CCA") and Other Vaccines, Pharmaceuticals and Products ("OVP"). CCA includes, primarily for canine and feline use, point of care laboratory testing instruments and supplies under a unique multi-year Reset Subscription model, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings such as in-clinic diagnostic tests and heartworm preventive products. OVP includes, primarily for herd animal health, private label vaccine and pharmaceutical production under third party agreements and channels. For further information on Heska and its products, visit www.heska.com.

 

SOURCE Heska Corporation


These press releases may also interest you

at 17:31
Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness. Moreover,...

at 17:00
Avicanna Announces Closing of Non-brokered Private Placement
Avicanna Inc. ("Avicanna" or the "Company") a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has closed a non-brokered private...

at 16:46
Darling Ingredients Inc. to Release First Quarter 2024 Financial Results
Darling Ingredients Inc. announced today that it will host a conference call on Thursday, April 25, 2024, at 9 a.m. Eastern Time (8 a.m. Central Time) to discuss first quarter 2024 financial results, which will be released earlier that day, and...

at 16:45
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic...

at 16:45
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation , a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron common stock as inducements to newly hired employees in connection...

at 16:35
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan
DermTech, Inc. (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring...

More news about Health...


News published on and distributed by: